XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
At-the-market offering
Common Stock
Additional Paid-In Capital
At-the-market offering
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
RareStone Group Ltd.
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
At-the-market offering
RareStone Group Ltd.
Total
Beginning balance at Dec. 31, 2021   $ 50   $ 813,041   $ (1) $ (528,939)     $ 284,151
Beginning balance (in shares) at Dec. 31, 2021   50,283,574                
Increase (Decrease) in Stockholders' Equity                    
Stock-based compensation expense       4,611           4,611
Issuance of common stock in connection with ESPP       399           399
Issuance of common stock in connection with ESPP (in shares)   61,518                
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)   48,639                
Unrealized loss or gain on marketable securities           (628)       (628)
Net loss             (52,764)     (52,764)
Ending balance at Mar. 31, 2022   $ 50   818,051   (629) (581,703)     235,769
Ending balance (in shares) at Mar. 31, 2022   50,393,731                
Beginning balance at Dec. 31, 2021   $ 50   813,041   (1) (528,939)     284,151
Beginning balance (in shares) at Dec. 31, 2021   50,283,574                
Increase (Decrease) in Stockholders' Equity                    
Net loss                   (138,626)
Ending balance at Sep. 30, 2022   $ 56   949,043   (339) (667,565)     281,195
Ending balance (in shares) at Sep. 30, 2022   55,756,256                
Beginning balance at Mar. 31, 2022   $ 50   818,051   (629) (581,703)     235,769
Beginning balance (in shares) at Mar. 31, 2022   50,393,731                
Increase (Decrease) in Stockholders' Equity                    
Stock-based compensation expense       5,137           5,137
Issuance of common stock in connection with exercise of stock options (in shares)   60,439                
Unrealized loss or gain on marketable securities           23       23
Unrealized (loss) reversal on RareStone equity           (300)       (300)
Reclassification of losses on RareStone equity into net loss                 $ 300  
Net loss             (45,001)     (45,001)
Ending balance at Jun. 30, 2022   $ 50   823,188   (906) (626,704)     195,628
Ending balance (in shares) at Jun. 30, 2022   50,454,170                
Increase (Decrease) in Stockholders' Equity                    
Stock-based compensation expense       4,796           4,796
Issuance of common stock in connection with ESPP       227           227
Issuance of common stock in connection with ESPP (in shares)   31,414                
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units   $ 1   3,863           3,864
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)   470,672                
Unrealized loss or gain on marketable securities           267       267
Issuance of common stock, net of offering costs   $ 5   116,969           116,974
Issuance of common stock, net of offering costs (in shares)   4,800,000                
Reclassification of losses on RareStone equity into net loss         $ 300       $ 300  
Net loss             (40,861)     (40,861)
Ending balance at Sep. 30, 2022   $ 56   949,043   (339) (667,565)     281,195
Ending balance (in shares) at Sep. 30, 2022   55,756,256                
Beginning balance at Dec. 31, 2022   $ 56   974,356   (92) (710,058)     264,262
Beginning balance (in shares) at Dec. 31, 2022   56,612,429                
Increase (Decrease) in Stockholders' Equity                    
Stock-based compensation expense       6,376           6,376
Issuance of common stock in connection with ESPP       665           665
Issuance of common stock in connection with ESPP (in shares)   32,169                
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units       553           553
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)   207,806                
Foreign currency translation adjustment           21       21
Unrealized loss or gain on marketable securities           65       65
Net loss             (52,179)     (52,179)
Ending balance at Mar. 31, 2023   $ 56   981,950   (6) (762,237)     219,763
Ending balance (in shares) at Mar. 31, 2023   56,852,404                
Beginning balance at Dec. 31, 2022   $ 56   974,356   (92) (710,058)     264,262
Beginning balance (in shares) at Dec. 31, 2022   56,612,429                
Increase (Decrease) in Stockholders' Equity                    
Foreign currency translation adjustment                   49
Net loss                   (143,045)
Ending balance at Sep. 30, 2023   $ 59   1,050,631   (113) (853,103)     197,474
Ending balance (in shares) at Sep. 30, 2023   59,089,352                
Beginning balance at Mar. 31, 2023   $ 56   981,950   (6) (762,237)     219,763
Beginning balance (in shares) at Mar. 31, 2023   56,852,404                
Increase (Decrease) in Stockholders' Equity                    
Stock-based compensation expense       8,891           8,891
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units   $ 1   341           342
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)   43,664                
Foreign currency translation adjustment           (48)       (48)
Unrealized loss or gain on marketable securities           40       40
Net loss             (46,703)     (46,703)
Ending balance at Jun. 30, 2023   $ 57   991,182   (14) (808,940)     182,285
Ending balance (in shares) at Jun. 30, 2023   56,896,068                
Increase (Decrease) in Stockholders' Equity                    
Stock-based compensation expense       8,612           8,612
Issuance of common stock in connection with ESPP       388           388
Issuance of common stock in connection with ESPP (in shares)   17,650                
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units       1,576           1,576
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)   156,389                
Foreign currency translation adjustment           76       76
Net unrealized losses on short-term investments           (175)       (175)
Issuance of common stock, net of offering costs $ 2   $ 48,873         $ 48,875    
Issuance of common stock, net of offering costs (in shares) 2,019,245                  
Net loss             (44,163)     (44,163)
Ending balance at Sep. 30, 2023   $ 59   $ 1,050,631   $ (113) $ (853,103)     $ 197,474
Ending balance (in shares) at Sep. 30, 2023   59,089,352